← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleRochePhase 2

Belinostat, carboplatin, paclitaxel and bevacizumab (Belinostat, carboplatin, paclitaxel and bevacizumab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleFujian Medical UniversityApproved

Bemosuzumab (Bemosuzumab)

Thyroid Neoplasms · Thyroid Neoplasms

#ThyroidNeoplasms#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleInternational Extranodal Lympho…Phase 2

Bendamustine and Rituximab (Bendamustine and Rituximab)

Marginal Zone B-cell Lymphoma · Marginal Zone B-cell Lymphoma

#MarginalZoneB-cellLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 91%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bendamustine, Rituximab, Lenalidomide (Bendamustine, Rituximab, Lenalidomide)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Bevacizumab (Avastin, Bevacizumab, Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec))

Pulmonary Veno Occlusive Disease · Pulmonary Veno Occlusive Disease

#PulmonaryVenoOcclusiveDisease#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab (Avastin, Bevacizumab, Bevacizumab (Avastin), Verteporfin (Visudyne))

Neovascular Age-related Macular Degeneration · Neovascular Age-related Macular Degenera

#NeovascularAge-relatedMacularDeg#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

adjuvant (Bevacizumab, Bevacizumab (adjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 41.7%임상시험 1상태 RECRUITING
AntibodyBiologicstaleRochePhase 1

aka Avastin or Rhu MAb VEGF (Bevacizumab, Bevacizumab (aka Avastin or Rhu MAb VEGF))

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

and approved biosimilars (Bevacizumab, Bevacizumab (and approved biosimilars))

Solid Tumor; Colorectal Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Bevacizumab, Bevacizumab (drug), Herceptin (drug), drug)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 73%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab + Capecitabine + Radiotherapy (Bevacizumab + Capecitabine + Radiotherapy)

Rectal Cancer · Rectal Cancer

#RectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Bevacizumab + blood samples (Bevacizumab + blood samples)

Colorectal Cancer; Metastasis · Colorectal Cancer

#ColorectalCancer#Antibody#Preclinical#항체#면역항체+3
효능 ORR 41.7%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab + modified FOLFIRINOX (Bevacizumab + modified FOLFIRINOX)

Mucinous Ovarian Cancer; Fallopian Tube Cancer · Mucinous Ovarian Cancer

#MucinousOvarianCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab Biosimilar HLX04 (Bevacizumab Biosimilar HLX04)

Non-Squamous Non-Small Cell Lung Cancer · Non-Squamous Non-Small Cell Lung Cancer

#Non-SquamousNon-SmallCellLungCan#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab Biosimilar IBI305 (Bevacizumab Biosimilar IBI305)

Post-orthotopic Liver Transplantation; Hepatocellular Carcinoma Recurrent · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

Bevacizumab Biosimilar IBI305 plus sintilimab (Bevacizumab Biosimilar IBI305 plus sintilimab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Bevacizumab Combined With Gefitinib (Bevacizumab Combined With Gefitinib)

PFS · PFS

#PFS#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE

28 / 92 페이지

← 이전다음 →